

Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of B Development of Osteolytic Bone Disease in Multiple My

Journal of Bone and Mineral Research

24, 425-436

DOI: [10.1359/jbmr.081104](https://doi.org/10.1359/jbmr.081104)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Pathogenesis and management of myeloma bone disease. Expert Review of Hematology, 2009, 2, 385-398. | 1.0 | 45 |
| 2 | Immunomodulation of Multiple Myeloma Bone Disease. Clinical Reviews in Bone and Mineral Metabolism, 2009, 7, 293-300. | 1.3 | 4 |
| 3 | The role of bisphosphonates in multiple myeloma. Current Hematologic Malignancy Reports, 2009, 4, 108-112. | 1.2 | 17 |
| 4 | Wnt signaling during fracture repair. Current Osteoporosis Reports, 2009, 7, 64-69. | 1.5 | 74 |
| 5 | Myeloma Bone Disease. Journal of Bone and Mineral Research, 2009, 24, 1783-1788. | 3.1 | 11 |
| 6 | Wnt signaling as a therapeutic target for bone diseases. Expert Opinion on Therapeutic Targets, 2009, 13, 485-496. | 1.5 | 205 |
| 7 | Mechanisms of bone repair and regeneration. Trends in Molecular Medicine, 2009, 15, 417-429. | 3.5 | 259 |
| 8 | Dickkopf-1: a suitable target for the management of myeloma bone disease. Expert Opinion on Therapeutic Targets, 2009, 13, 839-848. | 1.5 | 62 |
| 9 | Novel Immunotherapies. Cancer Journal (Sudbury, Mass), 2009, 15, 502-510. | 1.0 | 31 |
| 10 | Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood, 2009, 114, 371-379. | 0.6 | 364 |
| 11 | Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma. Yearbook of Endocrinology, 2009, 2009, 213-216. | 0.0 | 165 |
| 12 | Multiple bone lesions and hypercalcemia presented in diffuse large B cell lymphoma: mimicking multiple myeloma?. International Journal of Hematology, 2010, 91, 716-722. | 0.7 | 10 |
| 13 | Preventing metastases to bone: Denosumab or bisphosphonates?. Journal of Bone and Mineral Research, 2010, 25, 437-439. | 3.1 | 4 |
| 14 | Advances in the understanding of myeloma bone disease and tumour growth. British Journal of Haematology, 2010, 149, 311-321. | 1.2 | 82 |
| 15 | Wnt/Frizzled receptor signaling in osteoporosis. , 0, , 398-414. | | 0 |
| 16 | SOST and DKK: Antagonists of LRP Family Signaling as Targets for Treating Bone Disease. Journal of Osteoporosis, 2010, 2010, 1-9. | 0.1 | 32 |
| 17 | p21CIP-1/WAF-1 Induction Is Required to Inhibit Prostate Cancer Growth Elicited by Deficient Expression of the Wnt Inhibitor Dickkopf-1. Cancer Research, 2010, 70, 9916-9926. | 0.4 | 39 |
| 18 | Osteoblastogenesis and tumor growth in myeloma. Leukemia and Lymphoma, 2010, 51, 213-220. | 0.6 | 48 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Targeting the Wnt signaling pathway for the development of novel therapies for osteoporosis. <i>Expert Review of Endocrinology and Metabolism</i> , 2010, 5, 711-722. | 1.2 | 5 |
| 20 | Generation and Selection of Novel Fully Human Monoclonal Antibodies That Neutralize Dickkopf-1 (DKK1) Inhibitory Function in Vitro and Increase Bone Mass in Vivo. <i>Journal of Biological Chemistry</i> , 2010, 285, 40135-40147. | 1.6 | 89 |
| 21 | Le vieillissement osseux: les nouveaux acteurs de communication intercellulaire. <i>Medecine Et Longevite</i> , 2010, 2, 200-204. | 0.1 | 1 |
| 22 | Metastasis and bone loss: Advancing treatment and prevention. <i>Cancer Treatment Reviews</i> , 2010, 36, 615-620. | 3.4 | 121 |
| 23 | Osteocytes and WNT: the Mechanical Control of Bone Formation. <i>Journal of Dental Research</i> , 2010, 89, 331-343. | 2.5 | 104 |
| 24 | Emerging Targets in Osteoporosis Disease Modification. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 4332-4353. | 2.9 | 28 |
| 25 | Emerging therapies in metastatic bone pain. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 441-458. | 1.0 | 15 |
| 26 | New targets for intervention in the treatment of postmenopausal osteoporosis. <i>Nature Reviews Rheumatology</i> , 2011, 7, 631-638. | 3.5 | 116 |
| 27 | Tumor-host cell interactions in the bone disease of myeloma. <i>Bone</i> , 2011, 48, 121-128. | 1.4 | 49 |
| 28 | Effects of cobalt and chromium ions at clinically equivalent concentrations after metal-on-metal hip replacement on human osteoblasts and osteoclasts: Implications for skeletal health. <i>Bone</i> , 2011, 49, 717-723. | 1.4 | 94 |
| 29 | Emerging therapeutic opportunities for skeletal restoration. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 141-156. | 21.5 | 125 |
| 30 | Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBF β -dependent expression of the Wnt antagonist, sclerostin. <i>Breast Cancer Research</i> , 2011, 13, R106. | 2.2 | 89 |
| 31 | Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2011, 17, 1278-1286. | 3.2 | 161 |
| 32 | Osteoporosis: now and the future. <i>Lancet, The</i> , 2011, 377, 1276-1287. | 6.3 | 1,973 |
| 33 | The Role of the BMP Signaling Antagonist Noggin in the Development of Prostate Cancer Osteolytic Bone Metastasis. <i>PLoS ONE</i> , 2011, 6, e16078. | 1.1 | 50 |
| 34 | Pharmaceutical inhibition of glycogen synthetase kinase-3 β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model. <i>Blood</i> , 2011, 117, 1641-1651. | 0.6 | 34 |
| 35 | Monoclonal antibodies in the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2011, 154, 745-754. | 1.2 | 68 |
| 36 | Antagonists of LRP6 regulate PTH-induced cAMP generation. <i>Annals of the New York Academy of Sciences</i> , 2011, 1237, 39-46. | 1.8 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice. <i>Journal of Bone and Mineral Metabolism</i> , 2011, 29, 141-148. | 1.3 | 57 |
| 38 | Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma. <i>International Journal of Hematology</i> , 2011, 94, 334-343. | 0.7 | 60 |
| 39 | Bone Anabolic Agents for the Treatment of Multiple Myeloma. <i>Cancer Microenvironment</i> , 2011, 4, 339-349. | 3.1 | 20 |
| 40 | Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 2610-2621. | 3.1 | 106 |
| 41 | The P2Y6 Receptor Stimulates Bone Resorption by Osteoclasts. <i>Endocrinology</i> , 2011, 152, 3706-3716. | 1.4 | 44 |
| 42 | Expression of multiple myeloma associated markers in bone marrow spicules using a novel immunohistochemical technique. <i>Biotechnic and Histochemistry</i> , 2011, 86, 119-123. | 0.7 | 6 |
| 43 | Antibody-Based Therapies in Multiple Myeloma. <i>Bone Marrow Research</i> , 2011, 2011, 1-14. | 1.7 | 46 |
| 44 | A Rate-Limiting Role for Dickkopf-1 in Bone Formation and the Remediation of Bone Loss in Mouse and Primate Models of Postmenopausal Osteoporosis by an Experimental Therapeutic Antibody. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 338, 568-578. | 1.3 | 73 |
| 45 | The Microenvironment and Molecular Biology of the Multiple Myeloma Tumor. <i>Advances in Cancer Research</i> , 2011, 110, 19-42. | 1.9 | 61 |
| 46 | Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-28. | 3.3 | 28 |
| 47 | Reduced Bone Turnover in Mice Lacking the P2Y13 Receptor of ADP. <i>Molecular Endocrinology</i> , 2012, 26, 142-152. | 3.7 | 51 |
| 48 | A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 12207-12212. | 3.3 | 41 |
| 49 | Monoclonal antibody-based immunotherapy for multiple myeloma. <i>Immunotherapy</i> , 2012, 4, 919-938. | 1.0 | 8 |
| 50 | Bone Marrow Stromal Cells Create a Permissive Microenvironment for Myeloma Development: A New Stromal Role for Wnt Inhibitor Dkk1. <i>Cancer Research</i> , 2012, 72, 2183-2189. | 0.4 | 70 |
| 51 | p38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction. <i>Cancer Research</i> , 2012, 72, 6393-6402. | 0.4 | 66 |
| 52 | Recent developments in bone anabolic therapy for osteoporosis. <i>Expert Review of Endocrinology and Metabolism</i> , 2012, 7, 677-685. | 1.2 | 6 |
| 53 | Wnt Signaling in Bone Development and Disease: Making Stronger Bone with Wnts. <i>Cold Spring Harbor Perspectives in Biology</i> , 2012, 4, a007997-a007997. | 2.3 | 164 |
| 54 | A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts. <i>Journal of Bone Oncology</i> , 2012, 1, 47-56. | 1.0 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Wnt and Wnt inhibitors in bone metastasis. BoneKEy Reports, 2012, 1, 101. | 2.7 | 29 |
| 56 | Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo. Clinical and Experimental Metastasis, 2012, 29, 927-938. | 1.7 | 43 |
| 57 | Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases. Endocrine Reviews, 2012, 33, 747-783. | 8.9 | 356 |
| 58 | Update on Wnt signaling in bone cell biology and bone disease. Gene, 2012, 492, 1-18. | 1.0 | 347 |
| 59 | Prevention and Treatment of Myeloma Bone Disease. Current Hematologic Malignancy Reports, 2012, 7, 249-257. | 1.2 | 11 |
| 60 | Mechanisms of multiple myeloma bone disease. BoneKEy Reports, 2012, 1, 135. | 2.7 | 43 |
| 61 | Transcriptional Silencing of the Wnt-Antagonist DKK1 by Promoter Methylation Is Associated with Enhanced Wnt Signaling in Advanced Multiple Myeloma. PLoS ONE, 2012, 7, e30359. | 1.1 | 41 |
| 62 | A Mouse with an N-Ethyl-N-Nitrosourea (ENU) Induced Trp589Arg Galnt3 Mutation Represents a Model for Hyperphosphataemic Familial Tumoural Calcinosis. PLoS ONE, 2012, 7, e43205. | 1.1 | 19 |
| 63 | A mouse model for spondyloepiphyseal dysplasia congenita with secondary osteoarthritis due to a <i>Col2a1</i> mutation. Journal of Bone and Mineral Research, 2012, 27, 413-428. | 3.1 | 31 |
| 64 | Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia, 2012, 26, 199-213. | 3.3 | 72 |
| 65 | Resolution of inflammation induces osteoblast function and regulates the Wnt signaling pathway. Arthritis and Rheumatism, 2012, 64, 1540-1550. | 6.7 | 121 |
| 66 | Potential Role for Therapies Targeting DKK1, LRP5, and Serotonin in the Treatment of Osteoporosis. Current Osteoporosis Reports, 2012, 10, 93-100. | 1.5 | 31 |
| 67 | Osteocyte Biology. , 2013, , 209-234. | | 5 |
| 68 | WNT Signaling in Skeletal Homeostasis and Diseases. , 2013, , 411-428. | | 3 |
| 69 | Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. European Journal of Haematology, 2013, 90, 441-468. | 1.1 | 46 |
| 70 | Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib. International Journal of Hematology, 2013, 98, 66-73. | 0.7 | 13 |
| 71 | Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches. Nature Reviews Endocrinology, 2013, 9, 575-583. | 4.3 | 247 |
| 72 | The Osteocyte: An Endocrine Cell and More. Endocrine Reviews, 2013, 34, 658-690. | 8.9 | 812 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. <i>Bone</i> , 2013, 53, 487-496. | 1.4 | 65 |
| 74 | Dickkopf-1 is a key regulator of myeloma bone disease: Opportunities and challenges for therapeutic intervention. <i>Blood Reviews</i> , 2013, 27, 261-267. | 2.8 | 51 |
| 75 | New Approaches to Osteoporosis Therapeutics. , 2013, , 1963-1985. | | 0 |
| 76 | Role of the P2Y13 Receptor in the Differentiation of Bone Marrow Stromal Cells into Osteoblasts and Adipocytes. <i>Stem Cells</i> , 2013, 31, 2747-2758. | 1.4 | 58 |
| 77 | Autocrine stimulation of osteoblast activity by Wnt5a in response to TNF- α in human mesenchymal stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2013, 430, 1072-1077. | 1.0 | 69 |
| 78 | Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin. <i>Journal of Cell Biology</i> , 2013, 200, 537-549. | 2.3 | 157 |
| 79 | WNT signaling in bone homeostasis and disease: from human mutations to treatments. <i>Nature Medicine</i> , 2013, 19, 179-192. | 15.2 | 1,622 |
| 80 | The role of extracellular modulators of canonical Wnt signaling in bone metabolism and diseases. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 220-240. | 1.6 | 62 |
| 81 | LRP5 and LRP6 in development and disease. <i>Trends in Endocrinology and Metabolism</i> , 2013, 24, 31-39. | 3.1 | 177 |
| 82 | Wnt signaling in bone formation and its therapeutic potential for bone diseases. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2013, 5, 13-31. | 1.2 | 264 |
| 83 | The P2Y13 receptor regulates extracellular ATP metabolism and the osteogenic response to mechanical loading. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1446-1456. | 3.1 | 31 |
| 84 | Myeloma bone disease " pathogenesis of bone destruction and therapeutic strategies. , 0, , 96-109. | | 0 |
| 85 | Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma. <i>PLoS ONE</i> , 2013, 8, e74191. | 1.1 | 39 |
| 86 | Cellular Mechanisms of Multiple Myeloma Bone Disease. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-11. | 3.3 | 52 |
| 87 | Interaction among Cells of Bone, Immune System, and Solid Tumors Leads to Bone Metastases. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-7. | 3.3 | 15 |
| 88 | The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation <i>in vitro</i> : defining the stromal defect in myeloma. <i>British Journal of Haematology</i> , 2014, 167, 194-206. | 1.2 | 15 |
| 89 | Insights Into the Mechanisms of Sclerostin Action in Regulating Bone Mass Accrual. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 24-28. | 3.1 | 27 |
| 90 | A Phase <i>IB</i> multicentre dose-determination study of <i>BHQ</i> 880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. <i>British Journal of Haematology</i> , 2014, 167, 366-375. | 1.2 | 130 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Recent advances in antimultiple myeloma drug development. <i>Pharmaceutical Patent Analyst</i> , 2014, 3, 261-277. | 0.4 | 1 |
| 92 | Fluid and Electrolyte Abnormalities in Patients with Cancer. , 2014, , 167-182. | | 1 |
| 93 | Biology and management of myeloma-related bone disease. <i>Acta Haematologica Polonica</i> , 2014, 45, 107-121. | 0.1 | 1 |
| 94 | Signaling Between Tumor Cells and the Host Bone Marrow Microenvironment. <i>Calcified Tissue International</i> , 2014, 94, 125-139. | 1.5 | 22 |
| 95 | Targeting bone metastatic cancer: Role of the mTOR pathway. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 248-254. | 3.3 | 25 |
| 96 | Myeloma bone disease: pathogenesis, current treatments and future targets. <i>British Medical Bulletin</i> , 2014, 111, 117-138. | 2.7 | 61 |
| 97 | Secondary osteoporosis: Pathophysiology & diagnosis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 911-935. | 2.2 | 50 |
| 98 | Management of bone disease in multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 113-125. | 1.0 | 86 |
| 99 | Relevance of Wnt signaling for osteoanabolic therapy. <i>Molecular and Cellular Therapies</i> , 2014, 2, 22. | 0.2 | 6 |
| 100 | Dickkopf-1 is regulated by the mevalonate pathway in breast cancer. <i>Breast Cancer Research</i> , 2014, 16, R20. | 2.2 | 32 |
| 101 | Dickkopf-1 as a mediator and novel target in malignant bone disease. <i>Cancer Letters</i> , 2014, 346, 172-177. | 3.2 | 36 |
| 102 | Gene-expression and in vitro function of mesenchymal stromal cells are affected in juvenile myelomonocytic leukemia. <i>Haematologica</i> , 2015, 100, 1434-1441. | 1.7 | 5 |
| 103 | State-of-the-art of bone marrow imaging in multiple myeloma. <i>Current Opinion in Oncology</i> , 2015, 27, 540-550. | 1.1 | 4 |
| 104 | Bone fracture healing: Cell therapy in delayed unions and nonunions. <i>Bone</i> , 2015, 70, 93-101. | 1.4 | 330 |
| 105 | The osteoblastic niche in the context of multiple myeloma. <i>Annals of the New York Academy of Sciences</i> , 2015, 1335, 45-62. | 1.8 | 49 |
| 106 | The use of animal models in multiple myeloma. <i>Morphologie</i> , 2015, 99, 63-72. | 0.5 | 10 |
| 107 | A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease. <i>Bone</i> , 2015, 77, 57-68. | 1.4 | 38 |
| 108 | Transmembrane protein 64 reciprocally regulates osteoblast and adipocyte differentiation by modulating Wnt/ β -catenin signaling. <i>Bone</i> , 2015, 78, 165-173. | 1.4 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Multiple myeloma-related bone disease: state-of-art and next future treatments. International Journal of Hematologic Oncology, 2015, 4, 33-47. | 0.7 | 0 |
| 110 | Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma. British Medical Bulletin, 2015, 113, 15-30. | 2.7 | 16 |
| 111 | P38 regulates the Wnt inhibitor Dickkopf-1 in breast cancer. Biochemical and Biophysical Research Communications, 2015, 466, 728-732. | 1.0 | 11 |
| 112 | Pharmaceutical inhibition of glycogen synthetase kinase 3 beta suppresses wear debris-induced osteolysis. Biomaterials, 2015, 69, 12-21. | 5.7 | 34 |
| 113 | Effect of Recent Spinal Cord Injury on Wnt Signaling Antagonists (Sclerostin and Dkk-1) and Their Relationship With Bone Loss. A 12-Month Prospective Study. Journal of Bone and Mineral Research, 2015, 30, 1014-1021. | 3.1 | 29 |
| 114 | Tumor-bone interactions: there is no place like bone. , 2015, , 13-28. | | 0 |
| 115 | Treatment of post-menopausal osteoporosis: beyond bisphosphonates. Journal of Endocrinological Investigation, 2015, 38, 13-29. | 1.8 | 61 |
| 116 | In vivo models used in studies of bone metastases. , 2015, , 503-518. | | 1 |
| 117 | Medication-Related Osteonecrosis of the Jaw: New Insights into Molecular Mechanisms and Cellular Therapeutic Approaches. Stem Cells International, 2016, 2016, 1-16. | 1.2 | 46 |
| 118 | Modulating Dickkopf-1: A Strategy to Monitor or Treat Cancer?. Cancers, 2016, 8, 62. | 1.7 | 28 |
| 119 | Our periodontal tissue: a masterpiece of evolution. Journal of Clinical Periodontology, 2016, 43, 320-322. | 2.3 | 11 |
| 120 | Small molecule inhibitors of the Dishevelled-CXXC 5 interaction are new drug candidates for bone anabolic osteoporosis therapy. EMBO Molecular Medicine, 2016, 8, 375-387. | 3.3 | 32 |
| 121 | Serum DKK-1 level in the development of ankylosing spondylitis and rheumatic arthritis: a meta-analysis. Experimental and Molecular Medicine, 2016, 48, e228-e228. | 3.2 | 35 |
| 122 | New therapies in osteoporosis. Revista Colombiana De Reumatología (English Edition), 2016, 23, 34-43. | 0.1 | 0 |
| 123 | Bone Disease in Multiple Myeloma. Cancer Treatment and Research, 2016, 169, 251-270. | 0.2 | 23 |
| 124 | Multiple myeloma in the marrow: pathogenesis and treatments. Annals of the New York Academy of Sciences, 2016, 1364, 32-51. | 1.8 | 132 |
| 125 | Osteolytica: An automated image analysis software package that rapidly measures cancer-induced osteolytic lesions in in vivo models with greater reproducibility compared to other commonly used methods. Bone, 2016, 83, 9-16. | 1.4 | 12 |
| 126 | Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?. Immunotherapy, 2016, 8, 367-384. | 1.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 128 | p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells. <i>Cell Death and Disease</i> , 2016, 7, e2119-e2119. | 2.7 | 43 |
| 129 | Adipose, Bone, and Myeloma: Contributions from the Microenvironment. <i>Calcified Tissue International</i> , 2017, 100, 433-448. | 1.5 | 45 |
| 130 | Exploiting the WNT Signaling Pathway for Clinical Purposes. <i>Current Osteoporosis Reports</i> , 2017, 15, 153-161. | 1.5 | 10 |
| 131 | Low-Density Lipoprotein Receptor-Related Proteins in Skeletal Development and Disease. <i>Physiological Reviews</i> , 2017, 97, 1211-1228. | 13.1 | 27 |
| 132 | Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. <i>Blood</i> , 2017, 129, 3452-3464. | 0.6 | 153 |
| 133 | Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. <i>Leukemia</i> , 2017, 31, 2686-2694. | 3.3 | 101 |
| 134 | MECHANISMS IN ENDOCRINOLOGY: Genetics of human bone formation. <i>European Journal of Endocrinology</i> , 2017, 177, R69-R83. | 1.9 | 29 |
| 135 | Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease. <i>Current Osteoporosis Reports</i> , 2017, 15, 532-541. | 1.5 | 20 |
| 136 | An integrative model of prostate cancer interaction with the bone microenvironment. <i>Mathematical Biosciences</i> , 2017, 294, 1-14. | 0.9 | 22 |
| 137 | Biology and treatment of myeloma related bone disease. <i>Metabolism: Clinical and Experimental</i> , 2018, 80, 80-90. | 1.5 | 49 |
| 138 | Underlying Signaling Pathways and Therapeutic Applications of Pulsed Electromagnetic Fields in Bone Repair. <i>Cellular Physiology and Biochemistry</i> , 2018, 46, 1581-1594. | 1.1 | 71 |
| 139 | Wnt Signaling in Hematological Malignancies. <i>Progress in Molecular Biology and Translational Science</i> , 2018, 153, 321-341. | 0.9 | 40 |
| 140 | An <i>N</i> -Ethyl- <i>N</i> -Nitrosourea (ENU) Mutagenized Mouse Model for Autosomal Dominant Nonsyndromic Kyphoscoliosis Due to Vertebral Fusion. <i>JBMR Plus</i> , 2018, 2, 154-163. | 1.3 | 1 |
| 141 | Strong immunoexpression of dickkopf-1 is associated with response to bortezomib in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2670-2678. | 0.6 | 5 |
| 142 | The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis. <i>Journal of Cellular Physiology</i> , 2018, 233, 1156-1167. | 2.0 | 116 |
| 143 | The roles of signaling pathways in bone repair and regeneration. <i>Journal of Cellular Physiology</i> , 2018, 233, 2937-2948. | 2.0 | 290 |
| 144 | The Proteasome and Myeloma-Associated Bone Disease. <i>Calcified Tissue International</i> , 2018, 102, 210-226. | 1.5 | 15 |
| 145 | DKK1 and sclerostin are early markers of relapse in multiple myeloma. <i>Bone</i> , 2018, 113, 114-117. | 1.4 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 146 | Bone-Targeted Therapies in Cancer-Induced Bone Disease. <i>Calcified Tissue International</i> , 2018, 102, 227-250. | 1.5 | 80 |
| 147 | Homozygous Dkk1 Knockout Mice Exhibit High Bone Mass Phenotype Due to Increased Bone Formation. <i>Calcified Tissue International</i> , 2018, 102, 105-116. | 1.5 | 15 |
| 148 | Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. <i>Blood Cancer Journal</i> , 2018, 8, 105. | 2.8 | 113 |
| 149 | Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3924. | 1.8 | 41 |
| 150 | Bone-targeted agents in multiple myeloma. <i>Hematology Reports</i> , 2018, 10, 7401. | 0.3 | 12 |
| 151 | Dickkopf-1 (Dkk1) protein expression in breast cancer with special reference to bone metastases. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 763-775. | 1.7 | 27 |
| 152 | Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies. <i>Pharmaceutics</i> , 2018, 10, 202. | 2.0 | 29 |
| 153 | Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway. <i>Nature Reviews Endocrinology</i> , 2018, 14, 605-623. | 4.3 | 42 |
| 154 | Secondary Osteoporosis. , 2019, , 253-269. | | 2 |
| 155 | TGFÎ² Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 2311-2326. | 3.1 | 14 |
| 156 | Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2557. | 1.8 | 75 |
| 157 | The Emerging Role of Osteocytes in Cancer in Bone. <i>JBMR Plus</i> , 2019, 3, e10186. | 1.3 | 38 |
| 158 | Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. <i>Leukemia</i> , 2019, 33, 1063-1075. | 3.3 | 119 |
| 159 | Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells. <i>Bone</i> , 2019, 122, 82-92. | 1.4 | 13 |
| 160 | Serum DKK1 is correlated with Î³ peak of serum electrophoresis in multiple myeloma: a multicenter biomarker study. <i>Biomarkers in Medicine</i> , 2019, 13, 1297-1306. | 0.6 | 1 |
| 161 | Correlations of DKK1 with pathogenesis and prognosis of human multiple myeloma. <i>Cancer Biomarkers</i> , 2019, 24, 195-201. | 0.8 | 19 |
| 162 | Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 783-796. | 3.1 | 22 |
| 163 | Bone Metastases. , 2020, , 809-830.e3. | | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 164 | Why do myeloma patients have bone disease? A historical perspective. <i>Blood Reviews</i> , 2020, 41, 100646. | 2.8 | 13 |
| 165 | Circulating osteocyte-related biomarkers (vitamin D, sclerostin, dickkopf-1), hepcidin, and oxidative stress markers in early breast cancer: Their impact in disease progression and outcome. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2020, 204, 105773. | 1.2 | 7 |
| 166 | Bone metastases. <i>Nature Reviews Disease Primers</i> , 2020, 6, 83. | 18.1 | 246 |
| 167 | Toward a Mathematical Modeling of Diseases™ Impact on Bone Remodeling: Technical Review. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 584198. | 2.0 | 18 |
| 168 | Hematological Diseases and Osteoporosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3538. | 1.8 | 30 |
| 169 | Cellular Communication in Bone Homeostasis and the Related Anti-osteoporotic Drug Development. <i>Current Medicinal Chemistry</i> , 2020, 27, 1151-1169. | 1.2 | 18 |
| 170 | Evolving functions of Dickkopf-1 in cancer and immunity. <i>Cancer Letters</i> , 2020, 482, 1-7. | 3.2 | 25 |
| 171 | Impact of MGUS and myeloma on skeletal health. , 2021, , 1421-1437. | | 0 |
| 172 | Mechanical loading prevents bone destruction and exerts anti-tumor effects in the MOPC315.BM.Luc model of myeloma bone disease. <i>Acta Biomaterialia</i> , 2021, 119, 247-258. | 4.1 | 9 |
| 173 | Therapeutic targets in myeloma bone disease. <i>British Journal of Pharmacology</i> , 2021, 178, 1907-1922. | 2.7 | 18 |
| 174 | The signaling pathway in modulating bone metabolism after dental implant in diabetes. <i>Biocell</i> , 2021, 45, 1509-1519. | 0.4 | 1 |
| 175 | WNT signaling in skeletal homeostasis and diseases. , 2021, , 257-279. | | 3 |
| 176 | Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple myeloma. <i>Oncogene</i> , 2021, 40, 1231-1241. | 2.6 | 17 |
| 178 | Role of Osteocytes in Cancer Progression in the Bone and the Associated Skeletal Disease. <i>Current Osteoporosis Reports</i> , 2021, 19, 247-255. | 1.5 | 3 |
| 179 | Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton™s Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3840. | 1.8 | 3 |
| 180 | Animal Models of Multiple Myeloma Bone Disease. <i>Frontiers in Genetics</i> , 2021, 12, 640954. | 1.1 | 5 |
| 181 | An Improved Animal Model of Multiple Myeloma Bone Disease. <i>Cancers</i> , 2021, 13, 4277. | 1.7 | 4 |
| 182 | Bone marrow/bone pre-metastatic niche for breast cancer cells colonization: The role of mesenchymal stromal cells. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 164, 103416. | 2.0 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 183 | A Novel Approach for the Discovery of Biomarkers of Radiotherapy Response in Breast Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 796. | 1.1 | 7 |
| 184 | Myelomaâ€“Bone Interaction: A Vicious Cycle via TAK1â€“PIM2 Signaling. <i>Cancers</i> , 2021, 13, 4441. | 1.7 | 5 |
| 185 | Nonlinear modeling and control strategies for bone diseases based on TGF β ² and Wnt factors. <i>Communications in Nonlinear Science and Numerical Simulation</i> , 2021, 100, 105842. | 1.7 | 1 |
| 186 | Myeloma Bone Disease: The Osteoblast in the Spotlight. <i>Journal of Clinical Medicine</i> , 2021, 10, 3973. | 1.0 | 7 |
| 187 | InÂvivo models used in studies of bone metastases. , 2022, , 35-53. | | 2 |
| 188 | Biological relationship between bone and myeloma cells. , 2022, , 1005-1017. | | 0 |
| 190 | The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression. <i>Cancers</i> , 2021, 13, 217. | 1.7 | 99 |
| 191 | Antibody-Based Therapies in Multiple Myeloma. , 2013, , 43-71. | | 1 |
| 192 | Novel Drugs in Myeloma: Harnessing Tumour Biology to Treat Myeloma. <i>Recent Results in Cancer Research</i> , 2011, 183, 151-187. | 1.8 | 7 |
| 193 | Bone Metastases. , 2014, , 739-763.e3. | | 3 |
| 194 | Rationale for targeting the Wnt signalling modulator Dickkopfâ€“1 for oncology. <i>British Journal of Pharmacology</i> , 2017, 174, 4637-4650. | 2.7 | 100 |
| 195 | A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model. <i>Oncotarget</i> , 2016, 7, 21114-21123. | 0.8 | 56 |
| 196 | SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma. <i>Oncotarget</i> , 2016, 7, 30712-30729. | 0.8 | 19 |
| 197 | Wnt and the Wnt signaling pathway in bone development and disease. <i>Frontiers in Bioscience - Landmark</i> , 2014, 19, 379. | 3.0 | 190 |
| 198 | Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics. <i>World Journal of Stem Cells</i> , 2014, 6, 322. | 1.3 | 36 |
| 199 | Bone anabolics in osteoporosis: Actuality and perspectives. <i>World Journal of Orthopedics</i> , 2014, 5, 247. | 0.8 | 26 |
| 200 | Evaluation of circulating Dickkopf-1 as a prognostic biomarker in ovarian cancer patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 109-117. | 1.4 | 4 |
| 201 | Osteoclast Activation in Multiple Myeloma. , 2010, , 183-198. | | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 202 | Proteasome Inhibitors and the Wnt Signaling Pathway in Myeloma Bone Disease. , 2010, , 211-229. | | 1 |
| 203 | Murine Models of Myeloma Bone Disease: The Importance of Choice. , 2010, , 151-168. | | 0 |
| 204 | In vivo Models Used in Studies of Bone Metastases. , 2010, , 347-363. | | 0 |
| 205 | Role of Osteoblast in Myeloma Pathology. , 2013, , 203-214. | | 0 |
| 206 | Role of Bone Disease in the Pathogenesis of Multiple Myeloma. , 2013, , 97-120. | | 2 |
| 207 | Novel Antigenic Targets for Immunotherapy in Myeloma. , 2013, , 25-42. | | 0 |
| 208 | The Effect of Novel Anti-myeloma Agents on Bone Metabolism. , 2013, , 257-275. | | 0 |
| 209 | Myeloma Bone Disease. , 2014, , 211-223. | | 0 |
| 210 | Myeloma Bone Disease. , 2020, , 342-354. | | 0 |
| 211 | Role of Osteoblasts in Cancer-Induced Bone Disease. , 2020, , 201-218. | | 1 |
| 213 | DKK1 maintained cancer stem-like properties of esophageal carcinoma cells via ALDH1A1/SOX2 axis. International Journal of Clinical and Experimental Pathology, 2017, 10, 9489-9495. | 0.5 | 6 |
| 214 | Drug Discovery of DKK1 Inhibitors. Frontiers in Pharmacology, 2022, 13, 847387. | 1.6 | 16 |
| 215 | Pathogenesis and Treatment of Myeloma-Related Bone Disease. International Journal of Molecular Sciences, 2022, 23, 3112. | 1.8 | 16 |
| 216 | Dickkopf1 (Dkk1) Alleviates Vascular Calcification by Regulating the Degradation of Phospholipase D1 (PLD1). Journal of Cardiovascular Translational Research, 2022, 15, 1327-1339. | 1.1 | 5 |
| 217 | Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Biological Carriers for Drug Delivery in Cancer Therapy. Frontiers in Bioengineering and Biotechnology, 2022, 10, 882545. | 2.0 | 4 |
| 218 | Advances in Our Understanding of the Mechanism of Action of Drugs (including Traditional Chinese) Tj ETQq1 1 0.784314 rgBT /Overbo | 1.6 | 11 |
| 219 | Pathophysiology and therapeutic advances in myeloma bone disease. Chronic Diseases and Translational Medicine, 2022, 8, 264-270. | 0.9 | 2 |
| 220 | The role of the bone microenvironment in regulating myeloma residual disease and treatment. Frontiers in Oncology, 0, 12, . | 1.3 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 221 | New Emerging Biomarkers for Bone Disease: Sclerostin and Dickkopf-1 (DKK1). <i>Calcified Tissue International</i> , 2023, 112, 243-257. | 1.5 | 14 |
| 222 | Preventing osteolytic lesions and osteomyelitis in multiple myeloma. <i>Journal of Bone Oncology</i> , 2022, 37, 100460. | 1.0 | 4 |
| 223 | Wnt regulation of hematopoietic stem cell development and disease. <i>Current Topics in Developmental Biology</i> , 2023, , . | 1.0 | 0 |
| 225 | Multi-Targeting DKK1 and LRP6 Prevents Bone Loss and Improves Fracture Resistance in Multiple Myeloma. <i>Journal of Bone and Mineral Research</i> , 2020, 38, 814-828. | 3.1 | 6 |
| 226 | Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors. <i>International Journal of Hematology</i> , 0, , . | 0.7 | 0 |